Monday, October 26, 2026 · Daily editionET --:--:--

Finished

Prospective Clinical Study to Assess the Safety and Efficacy of Versius, in Transoral Robotic Surgery

NCT06112535 · CMR Surgical Ltd · Updated 25 June 2025

What is being tested
Versius Surgical System
For
Squamous Cell Carcinoma of the Oropharynx; Squamous Cell Carcinoma, Unknown Primary
Kind of study
Tests a treatment or device on volunteers. No drug phase (a device or procedure study).
Who can join
Ages 18 years and older. About 60 people. The full rules are on the registry page.
Where
United Kingdom
When
Starts or started 13 Dec 2023, ends 22 April 2025. Registered 1 Nov 2023.
Results
None posted yet.

In the researchers' words

This is a single-arm, single site, multi-surgeon prospective feasibility study for transoral robot assisted surgery (TORS) with the Versius Surgical System. Versius is a robotic system designed to help in the accurate control of surgical instruments for minimal access ("keyhole") surgery. In TORS procedures surgical instruments are inserted through the mouth/throat to remove sick tissue rather than through skin incisions. The primary objective of this study will be to evaluate the safe use and performance of the Versius in transoral surgeries. Pre-clinical work has been conducted to ensure TORS with Versius is viable and safe; this will be one of the first in-human studies of TORS with Versius. This study will focus specifically on patients with cancerous tumours of the oropharynx (the mouth/throat) that need to be surgically removed. The safety of Versius for TORS will be mainly assessed by the rate of complications/adverse events up to 30 days after surgery, and the performance will be mainly assessed by the number of TORS cases successfully completed with Versius (i.e. without having to switch to another surgical technique).
ClinicalTrials.gov, NCT06112535

Sites

  • Liverpool Head and Neck Centre, ENT Department Liverpool University Hospitals NHS Foundation TrustLiverpool, United Kingdom